急性B型主动脉壁内血肿:腔内治疗时代的新见解
基于美国主动脉数据库2008至2022年70例急性B型主动脉壁内血肿患者的回顾性分析,43%(30/70)接受早期胸主动脉腔内修复(TEVAR,1组),57%(40/70)出院时接受最佳药物治疗(OMT,2组)。1组手术死亡为零,无卒中或脊髓缺血;2组随访期间50%(20/40)需延迟手术干预。
要点
- 1组TEVAR指征为穿透性动脉粥样硬化性溃疡或溃疡样突起(n=26)、胸降主动脉瘤(n=3)、进展为B型主动脉夹层(n=2)。
- 2组随访中50%(20/40)需延迟手术,其中TEVAR 14例、开放修复6例。
- 初始队列中71%需手术,9%进展为B型主动脉夹层,19%仅用OMT即消退或稳定。
核心结论
- 作者认为,急性B型主动脉壁内血肿最常见的病因是内膜缺损,进展为B型主动脉夹层及无内膜缺损的壁内血肿消退见于少部分患者。
- 作者认为,采用腔内治疗联合密切监测的积极策略可使急性B型主动脉壁内血肿获得良好的短期和长期结局。
研究设计与样本
- 美国主动脉数据库的回顾性分析,纳入2008至2022年70例急性B型主动脉壁内血肿患者。
- 按后续处理分为早期胸主动脉腔内修复组(TEVAR,1组,30例)与出院时最佳药物治疗组(OMT,2组,40例)。
主要发现
- 1组30/70(43%)接受TEVAR,2组40/70(57%)出院时接受OMT;两组年龄、人口学特征及合并症无显著差异。
- 1组TEVAR指征:穿透性动脉粥样硬化性溃疡或溃疡样突起(n=26)、胸降主动脉瘤(n=3)、进展为B型主动脉夹层(n=2)。
- 1组手术死亡为零,无患者发生卒中或脊髓缺血。
- 2组随访期间50%(20/40)需延迟手术干预,包括TEVAR 14例和开放修复6例;指征为出现穿透性动脉粥样硬化性溃疡或溃疡样突起(n=13)、进展为B型主动脉夹层(n=3)、合并动脉瘤样病变(n=4);20例未需手术。
- 初始队列中71%需手术,9%进展为B型主动脉夹层,19%仅用OMT即壁内血肿消退或稳定。
临床怎么用
- 作者提出,对急性B型主动脉壁内血肿采用腔内治疗联合密切监测的积极策略可获得良好的短期和长期结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathophysiology and behavior of acute type B intramural hematoma (TBIMH) is poorly understood. The purpose of this study is to characterize the pathophysiology, fate, and outcomes of TBIMH in the endovascular era. METHODS: A retrospective analysis of a US Aortic Database identified 70 patients with TBIMH from 2008 to 2022. Patients were divided into groups and analyzed based upon subsequent management: early thoracic endovascular aortic repair (TEVAR; Group 1) or hospital discharge on optimal medical therapy (OMT) (Group 2). RESULTS: Of 70 total patients, 43% (30/70) underwent TEVAR (Group 1) and 57% (40/70) were discharged on OMT (Group 2). There were no significant differences in age, demographics, or comorbidities between groups. Indications for TEVAR in Group 1 were as follows: 1) Penetrating atheroscletoic ulcer (PAU) or ulcer-like projection (n = 26); 2) Descending thoracic aortic aneurysm (n = 3); or 3) Progression to type B aortic dissection (TBAD) (n = 2). Operative mortality was zero. No patient suffered a stroke or spinal cord ischemia. During the follow-up period, 50% (20/40) of Group 2 patients required delayed surgical intervention, including TEVAR in 14 patients and open repair in 6 patients. Indications for surgical intervention were as follows: 1) Development of a PAU / ulcer-like projection (n = 13); 2) Progression to TBAD (n = 3), or 3) Concomitant aneurysmal disease (n = 4). Twenty patients did not require surgical intervention. Of the initial cohort, 71% of patients required surgery, 9% progressed to TBAD, and 19% had regression or stability of TBIMH with OMT alone. CONCLUSIONS: The most common etiology of TBIMH is an intimal defect. Progression to TBAD and intramural hematoma regression without an intimal defect occurs in a small percentage of patients. An aggressive strategy with endovascular therapy and close surveillance for TBIMH results in excellent short-term and long-term outcomes.
引用
- Crepy D'Orleans C, Duwayri YM, Zellner AB, et al. Acute Type B Intramural Hematoma: Novel Insights in the Endovascular Era. Ann Vasc Surg. 2024. PMID: 38301850. doi:10.1016/j.avsg.2023.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。